Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 7, 2022
Regulation
July 6 Quick Takes: FDA authorizes pharmacists to prescribe Paxlovid
Plus January PDUFA date for Biogen, Eisai Alzheimer’s therapy, and updates from Genentech, Sarepta, CytomX and more
BioCentury | Mar 12, 2022
Discovery & Translation
Translational highlights to watch for at AACR
BioCentury’s roundup of translational abstracts ahead of the 2022 American Association for Cancer Research conference
BioCentury | Mar 1, 2022
Deals
Feb. 28 Quick Takes: Heidelberg shares jump as Huadong takes stake
Plus FDA approves CTI’s pacritinib, Aurinia shares sink, Lexicon submission delayed, priority review for neoadjuvant Opdivo and more
BioCentury | Jun 23, 2021
Emerging Company Profile
CellPoint: bringing autologous CAR Ts to point of care
Emerging Company Profile: CellPoint aims to broaden access to CAR Ts with point-of-care manufacturing platform
BioCentury | May 26, 2021
Regulation
May 25 Quick Takes: Moderna to submit pediatric COVID vaccine data to regulators in early June; plus FDA guidance on bispecifics, TG, Asylia, Pieris, Nordic, Ziphius and Kyma
Moderna Inc. (NASDAQ:MRNA) will be the next company to bring a COVID-19 vaccine forward for authorization in adolescents, with plans to submit data from the Phase II/III TeenCOVE study of its COVID-19
BioCentury | Mar 1, 2021
Deals
With Phase III started in head and neck cancer, Debiopharm partners lead program with Germany’s Merck
Debiopharm will bank €188 million ($226.6 million) for pipeline development now that the biotech has partnered lead program xevinapant with Merck KGaA, adding the German biopharma’s
BioCentury | Jun 11, 2020
Deals
In course correction, AbbVie steers toward innovation with Genmab deal
AbbVie reaffirms its commitment to cancer, paying $750M up front for rights to a trio of Genmab bispecifics
BioCentury | Mar 28, 2020
Management Tracks
Bernard joins Qiagen as CEO; plus CytomX, Recursion, 89bio, Heptares, Fusion, Freeline, Cognition, I-Mab, Seres and more
BioCentury | Jan 18, 2019
Product Development
ImmunoGen’s milestone year
How 2019 could yield first evidence ImmunoGen’s new growth strategy is working
BioCentury | Nov 30, 2018
Targets & Mechanisms
Adhesion targets emerge at ASH 2018
Emerging science on adhesion molecules, RNA-binding proteins and more at ASH 2018
Items per page:
1 - 10 of 68